99 related articles for article (PubMed ID: 29166663)
1. A general model for predicting the binding affinity of reversibly and irreversibly dimerized ligands.
Foreman KW
PLoS One; 2017; 12(11):e0188134. PubMed ID: 29166663
[TBL] [Abstract][Full Text] [Related]
2. Optimization of tether length in nonglycosidically linked bivalent ligands that target sites 2 and 1 of a Shiga-like toxin.
Kitov PI; Shimizu H; Homans SW; Bundle DR
J Am Chem Soc; 2003 Mar; 125(11):3284-94. PubMed ID: 12630884
[TBL] [Abstract][Full Text] [Related]
3. Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site.
Lacham-Hartman S; Shmidov Y; Radisky ES; Bitton R; Lukatsky DB; Papo N
PLoS One; 2021; 16(11):e0249616. PubMed ID: 34847142
[TBL] [Abstract][Full Text] [Related]
4. Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation.
Hantgan RR; Rocco M; Nagaswami C; Weisel JW
Protein Sci; 2001 Aug; 10(8):1614-26. PubMed ID: 11468358
[TBL] [Abstract][Full Text] [Related]
5. A ligand-reversible dimerization system for controlling protein-protein interactions.
Rollins CT; Rivera VM; Woolfson DN; Keenan T; Hatada M; Adams SE; Andrade LJ; Yaeger D; van Schravendijk MR; Holt DA; Gilman M; Clackson T
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7096-101. PubMed ID: 10852943
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers.
Russo O; Berthouze M; Giner M; Soulier JL; Rivail L; Sicsic S; Lezoualc'h F; Jockers R; Berque-Bestel I
J Med Chem; 2007 Sep; 50(18):4482-92. PubMed ID: 17676726
[TBL] [Abstract][Full Text] [Related]
7. An improved reversibly dimerizing mutant of the FK506-binding protein FKBP.
Barrero JJ; Papanikou E; Casler JC; Day KJ; Glick BS
Cell Logist; 2016; 6(3):e1204848. PubMed ID: 27738551
[TBL] [Abstract][Full Text] [Related]
8. Bivalent ligands with long nanometer-scale flexible linkers.
Tian L; Heyduk T
Biochemistry; 2009 Jan; 48(2):264-75. PubMed ID: 19113836
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies.
Soulier JL; Russo O; Giner M; Rivail L; Berthouze M; Ongeri S; Maigret B; Fischmeister R; Lezoualc'h F; Sicsic S; Berque-Bestel I
J Med Chem; 2005 Oct; 48(20):6220-8. PubMed ID: 16190749
[TBL] [Abstract][Full Text] [Related]
10. Mutations affecting the oligomerization interface of G-protein-coupled receptors revealed by a novel de novo protein design framework.
Taylor MS; Fung HK; Rajgaria R; Filizola M; Weinstein H; Floudas CA
Biophys J; 2008 Apr; 94(7):2470-81. PubMed ID: 18178645
[TBL] [Abstract][Full Text] [Related]
11. New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity.
Sridhar J; Wei ZL; Nowak I; Lewin NE; Ayres JA; Pearce LV; Blumberg PM; Kozikowski AP
J Med Chem; 2003 Sep; 46(19):4196-204. PubMed ID: 12954072
[TBL] [Abstract][Full Text] [Related]
12. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity.
Wong DM; Greenblatt HM; Dvir H; Carlier PR; Han YF; Pang YP; Silman I; Sussman JL
J Am Chem Soc; 2003 Jan; 125(2):363-73. PubMed ID: 12517147
[TBL] [Abstract][Full Text] [Related]
13. Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands.
Hiller C; Kühhorn J; Gmeiner P
J Med Chem; 2013 Sep; 56(17):6542-59. PubMed ID: 23678887
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate.
Tamrazi A; Carlson KE; Daniels JR; Hurth KM; Katzenellenbogen JA
Mol Endocrinol; 2002 Dec; 16(12):2706-19. PubMed ID: 12456792
[TBL] [Abstract][Full Text] [Related]
15. RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev response element.
Luedtke NW; Liu Q; Tor Y
Biochemistry; 2003 Oct; 42(39):11391-403. PubMed ID: 14516190
[TBL] [Abstract][Full Text] [Related]
16. Calbindin D28k EF-hand ligand binding and oligomerization: four high-affinity sites--three modes of action.
Cedervall T; André I; Selah C; Robblee JP; Krecioch PC; Fairman R; Linse S; Akerfeldt KS
Biochemistry; 2005 Oct; 44(41):13522-32. PubMed ID: 16216075
[TBL] [Abstract][Full Text] [Related]
17. Reversible regulation of protein binding affinity by a DNA machine.
Zhou C; Yang Z; Liu D
J Am Chem Soc; 2012 Jan; 134(3):1416-8. PubMed ID: 22229476
[TBL] [Abstract][Full Text] [Related]
18. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
19. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
[TBL] [Abstract][Full Text] [Related]
20. Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonance.
He J; Liu G; Vanderheyden JL; Dou S; Mary R; Hnatowich DJ
Bioconjug Chem; 2005; 16(2):338-45. PubMed ID: 15769087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
